

FOR THE USE ONLY OF A VETERINARIAN OR
A HOSPITAL OR A LABORATORY OR A FARM

235569 R1

Combined Canine Distemper, Adenovirus, Parvovirus & Parainfluenza Vaccine, Live, Freeze dried.



Nobivac® **DHPPi**



NOT FOR HUMAN USE
FOR ANIMAL TREATMENT ONLY

WARNING: To be sold by retail on the prescription of a Veterinary Doctor only

DESCRIPTION

This vaccine contains freeze-dried, living, attenuated strains of canine distemper virus (CDV strain Onderstepoort), canine adenovirus type 2 (CAV2 strain Manhattan LPV3) canine parvovirus (CPV strain 154), and canine parainfluenza virus (CPI strain Cornell) grown in cell-line tissue culture.

COMPOSITION

Each 0.5 ml dose contains:

Active Ingredients	Quantity
Live infectious canine distemper virus (CDV) strain Onderstepoort, at least 4.0 log ₁₀ TCID ₅₀	A total of 0.375 ml infected tissue culture supernatant ¹
Live infectious canine adeno virus type 2 (CAV2) strain Manhattan LPV3, at least 4.0 log ₁₀ TCID ₅₀	
Live infectious canine parvovirus (CPV) strain 154, at least 7.0 log ₁₀ TCID ₅₀	
Live infectious canine parainfluenza virus (CPI), strain Cornell, at least 5.5 log ₁₀ TCID ₅₀	
Excipients	
Sorbitol	25 mg
Hydrolysed gelatin	12.5mg
Pancreatic digest of casein	12.5mg
Disodium phosphate dihydrate	0.062mg
Water for injection to	0.5ml
1: cell debris and traces of antibiotics may occur	

Each ml of diluent contains,
Disodium phosphate dihydrate 0.31mg, Potassium dihydrogen phosphate 0.21mg, Water for injections 1.0ml

INDICATIONS

For active immunization of dogs against canine distemper (CDV), canine contagious hepatitis caused by canine adenovirus type 1 (ICH), canine parvovirus disease (CPV) and respiratory disease caused by canine parainfluenza (CPI) and canine adenovirus type 2 (CAV2).

VACCINATION PROGRAMMES

A single dose of Nobivac DHPPi is sufficient to establish immunity in dogs of 12 weeks of age or older. Where earlier protection is required, a first dose of these components is recommended from 8-10 weeks of age but, because maternally derived antibody can interfere with the response to vaccination, a final dose should be given 2-4 weeks later i.e. at 12 weeks of age or older.

The following recommendations are included since it is likely that immunization with Nobivac DHPPi will perform part of a more comprehensive vaccination programme:

a. Programme for pups where exposure to distemper and/or parvo is possible before 8-10 weeks of age; and the MDA status of the pup is unknown:

- Age 4-6 weeks - Nobivac Parvo-C or Nobivac Puppy DP
- Age 8-10 weeks - Nobivac DHPPi with Nobivac Lepto or Nobivac L4
- Age 12 weeks - Nobivac DHPPi with Nobivac Lepto or Nobivac L4
Nobivac Rabies or Nobivac RL

b. Programme for pups where vaccination is started at the age of 8-10 weeks:

- Age 8-10 weeks - Nobivac DHPPi with Nobivac Lepto or Nobivac L4
- Age 12 weeks - Nobivac DHPPi with Nobivac Lepto or Nobivac L4
Nobivac Rabies or Nobivac RL

c. Programme for pups where vaccination is not started before the age of 12 weeks:

- Age 12 weeks - Nobivac DHPPi with Nobivac Lepto or Nobivac L4
Nobivac Rabies or Nobivac RL
- Age 14-16 weeks - Nobivac Lepto or Nobivac L4

REVACCINATION

It is recommended that dogs be revaccinated against:

1. Canine distemper, canine infectious hepatitis, canine parvovirus disease and respiratory disease caused by canine adenovirus type 2 - every 3 years.
2. Leptospirosis and respiratory disease caused by canine parainfluenza virus- every year.
3. Rabies- every 3 years (can be modified to comply with local regulations).

DOSAGE AND ADMINISTRATION

The contents of one vial of reconstituted vaccine should be injected subcutaneously. Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) Nobivac Lepto or Nobivac L4 (canine leptospirosis vaccine), one vial (1.0 ml) Nobivac Rabies, one vial (1.0 ml) Nobivac RL, or one vial (1.0 ml) of Nobivac Solvent. After reconstitution, the vaccine should be used within 30 minutes.

RECOMMENDATIONS FOR USE

Only healthy dogs should be vaccinated and an adequate clinical examination should be made prior to inoculation. Following vaccination, contact with potential sources of canine distemper virus, canine adenovirus and/or canine parvovirus infection should be avoided until 7 days after the inoculation. Sterile equipment should be used for administration, but avoid contamination of vaccine with traces of disinfectant or spirit.

CONTRA-INDICATIONS AND WARNINGS

Occasionally a mild anaphylactic type hypersensitivity reaction may occur after vaccination, as is possible with all foreign proteins. Such reactions are, in most cases, self limiting.

SHELF LIFE : 24 months.

The reconstituted vaccine shall be used within 30 minutes

PHARMACEUTICAL PRECAUTIONS AND STORAGE

Vaccine should be stored refrigerated (between +2° and 8°C) and protected from light. Care should be taken to avoid prolonged or repetitive exposure to high temperatures following withdrawal from the refrigerator prior to use; under hot summer conditions vaccine potency can be severely reduced within a few hours. Nobivac Solvent may be stored at room temperature.

PRESENTATION

Boxes containing vials of Nobivac DHPPi and vials of Nobivac Solvent, or boxes containing only vials of Nobivac DHPPi.

PACKAGE QUANTITY

Cartons of 10 single dose vials.

FURTHER INFORMATION

Experience has shown that the maternal antibody status of pups within a litter varies greatly and reliance should not be placed on serological examination of the bitch alone. Pregnant animals may be vaccinated.

Manufactured by:

Intervet International B.V.
Wim de Korverstraat 35
5831 AN Boxmeer
The Netherlands.

Imported and Marketed by:

Intervet India Pvt.Ltd.
Bldg. No. B-1, Godown No.12 to 16, Ground Floor & Godown No.12-A to 17-A First Floor,
House No. 233, Sagar Complex, Owali, Bhiwandi, Thane -421302, Maharashtra, India.

